



Common Sensing sells intellectual property assets to Bigfoot Biomedical®

Torreya Capital advised Common Sensing on this transaction

Cambridge, MA and Milpitas, CA, June 14, 2021

Bigfoot Biomedical announced that it has acquired the intellectual property assets of Common Sensing, a Cambridge-based company that develops and manufactures data-driven hardware and software solutions for people using injectable medicine, including Gocap. Gocap is a smart cap that automatically sends dosage and drug-delivery data from disposable pen-injectors to a mobile app and cloud platform.

Believing in the inherent synergy and increasing need for smart and connected technology within the diabetes industry, Bigfoot plans to use the acquisition to accelerate the advancement and expansion of their insulin-delivery product portfolio. Last month, Bigfoot received FDA clearance for its Bigfoot Unity™ Diabetes Management System featuring first-of-its-kind smart pen caps for insulin pens used to treat Type 1 and Type 2 diabetes. Integrated with Abbott's FreeStyle® Libre 2 system, the Bigfoot Unity System is the first and only solution to translate continuously monitored glucose data into on-demand insulin dose recommendations displayed right on the pen-cap screen for ease of use.

Torreya advised Common Sensing on the transaction. Torreya has advised tech-enabled life science companies on almost \$500 million in cumulative transaction value over the past year, demonstrating Torreya's commitment to its growing digital health practice. Torreya has advised on over 5 digital health transactions in the past 12 months..

ABOUT COMMON SENSING:

For more information about Common Sensing, please see: www.common-sensing.com

ABOUT BIGFOOT BIOMEDICAL®:

For more information about Bigfoot Biomedical, please see: www.bigfootbiomedical.com

Deal Press Release

Torreya Contact

LESLIE GAUTAM

Executive Director | New York Office

leslie.gautam@torreya.com | 212.257.5816 | [BIO](#)



Torreya is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.